Evaluation of the Diagnostic Sensitivity and Specificity of the Determine™ Syphilis Advanced Test.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-30

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, multi-centre study which will evaluate the diagnostic sensitivity and specificity of the Determine™ Syphilis Advanced test. The test is intended for professional use and the performance evaluation will be performed by professional healthcare and laboratory staff. The study will also have a retrospective study arm. The Determine™ Syphilis Advanced validation will be conducted in accordance with the World Health Organization\'s TSS-6 guidance on Syphilis rapid diagnostic tests, ISO 20916 (In vitro diagnostic medical devices - Clinical performance studies using specimens from human subjects - Good study practice), the study protocol, Good Clinical Practice and the respective local medical device laws.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NOWDx Test for the Diagnosis of Syphilis

NCT05063344

Syphilis Infection Treponema Pallidum Infection

COMPLETED

Multi-site Study of Rapid Diagnostic Syphilis Assays

NCT00300534

Syphilis

COMPLETED NA

Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis Syphilis Ab Test at the Point- Of-Care Sites

NCT06365606

Syphilis Infection Syphilis

COMPLETED NA

Modernizing Perinatal Syphilis Testing

NCT06082453

Syphilis

RECRUITING NA

Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System

NCT01543295

Syphilis

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Syphilis is a sexually transmitted infection (STI) caused by the spirochete Treponema pallidum subspecies. Globally, there were an estimated 7.1 million adults between 15 and 49 years of age who acquired syphilis in 2020. Syphilis is transmitted through sexual contact with infectious lesions, through blood transfusions and from mother-to-child during pregnancy; most infections are asymptomatic or unrecognized. Without treatment, the disease lasts for many years and is divided into stages: primary syphilis, secondary syphilis and latent syphilis. Mother-to-child transmission of syphilis (congenital syphilis) can adversely affect the foetus, but this can be averted by early detection and treatment of the mother during pregnancy.

Determine™ Syphilis Advanced is an in vitro, visually read, qualitative immunoassay for the detection of antibodies to Treponema pallidum, in human capillary and venous whole blood, plasma or serum.

The test is intended for professional use, and the performance evaluation will be performed by professional healthcare and laboratory staff. Results for all sample types (capillary and venous whole blood, plasma or serum) will be evaluated against reference test results. In addition, for a sub-cohort, the Determine™ Syphilis Advanced test will be compared with the commercially available Determine™ Syphilis TP and the SERODIA-TPPA tests. Study staff performing the testing using the Determine™ Syphilis Advanced will be blinded to the participants' syphilis infection status and all other study syphilis test results. The study will enrol prospective participants, and will also have a retrospective study group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Syphilis Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study staff performing the testing using the Determine™ Syphilis Advanced and Determine™ Syphilis TP testing will be blinded to the participants' syphilis infection status.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic test: Determine™ Syphilis Advanced test

Diagnostic test: Testing using the Determine™ Syphilis Advanced test will be conducted by study staff members.

Group Type EXPERIMENTAL

Diagnostic test: Determine™ Syphilis Advanced test

Intervention Type DIAGNOSTIC_TEST

The Determine™ Syphilis Advanced test is intended as an aid in detecting antibodies to Treponema pallidum in individuals with current or past infection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostic test: Determine™ Syphilis Advanced test

The Determine™ Syphilis Advanced test is intended as an aid in detecting antibodies to Treponema pallidum in individuals with current or past infection.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 12 years of age or older.
* The participant has confirmed previous / current syphilis according to their medical history, or the participant has unknown or negative syphilis infection status.
* The participant agrees to provide written informed consent.
* The participant agrees to complete all aspects of the study.

* The ethics committee-required written informed consent for study testing, or required documentation for sample use from a commercial vendor, is available.
* Sufficient volume for testing is available and the sample quality is adequate (for example no significant sample hemolysis)
* The sample must have been collected in EDTA vacutainers or serum tubes, processed to plasma and the plasma frozen within 36 hours of blood collection.

Exclusion Criteria

* Participant has already participated in this study on a previous occasion.
* Participant is deemed vulnerable and / or unfit for participation in the study by the Investigator.
* Participant is unwilling or unable to provide informed consent.
* Participant is currently enrolled in a study to evaluate an investigational new drug or vaccine.

* The sample has undergone more than one freeze thaw cycle
* The sample has been kept at -20 °C (± 5 °C) longer than 12 months. If the sample has been kept longer than 12 months, the storage temperature must have been colder than -20 °C (± 5 °C).

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes